hotspot -WSS

hotspot

author：focus 2025-08-23 18:39:07 - browse：99

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： AI can’t replace a physician’s gut feeling

WSS

Hospitals, health systems can help patients avoid medical debt

Key House panel plots a new health care package

Sanofi seeks simpler, safer CRISPR sickle cell cure

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Cosmetics set for new safety regulation. Why the industry is on board

Medicare to cover more brain scans for Alzheimer’s patients

leisure time

hotspot

entertainment

Apple is now the first public company to be valued at $3 trillion

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Dobbs anniversary: the lost opportunity of abortion as health care

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Will biotech layoffs continue through 2023?

Moonlake's readout produced a cash windfall. Risks remain

Group opposing PBM reform sets lobbying record

As demand for Covid shots wanes, Moderna seeks its next success

AI can’t replace a physician’s gut feeling

Wikipedia

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

'The boss' wants server deleted: New allegations emerge in Trump indictment

Medicare has a new plan to address drug shortages

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Cosmetics set for new safety regulation. Why the industry is on board

entertainment

leisure time

leisure time

focus